Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed

Journal of Infectious Diseases

Volumn 186, Issue 12, 2002, Pages 1844-1847

  Ristig, Maria B ^a   Crippin, Jeffrey ^a   Aberg, Judith A ^a   Powderly, William G ^a   Lisker Melman, Mauricio ^a   Kessels, Lisa ^a   Tebas, Pablo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; PRIORITY JOURNAL; TOXIC HEPATITIS; TREATMENT FAILURE; VIRUS LOAD;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PILOT PROJECTS; TIME FACTORS; VIRAL LOAD;

EID: 0037115019     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345770     Document Type: Article

References (16)

1. Wolfe M, Hanson DL, Selik R, Swerdlow DL. Deaths from non-AIDS-related diseases have increased as a proportion of deaths of HIV-infected persons since the advent of HAART [abstract 14]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle, WA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002: 57.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
4. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: Mechanisms and clinical implications. Drug Resist Update 2001;4:118-28.
5. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12:67-71.
6. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
7. Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002;24:173-81.
8. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001:32:963-9.
9. Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000; 7:79-83.
10. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology 2000; 31:241-6.
11. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-23.
12. Bochet M, Tubiana R, Benhamou Y, et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients coinfected with HIV/HBV [abstract 675-M]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002; 294.
13. Cooper D, Cheng A, Coakley D, et al. Anti-HBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV coinfected [abstract 124]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health,2002; 94.
14. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus- infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182:1375-84.
15. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000; 14:2495-501.
16. Delaugerre C. MA-G, Thibault V. et al. HIV-type 1 reverse transcriptase resistance mutations in hepatitis B virus-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002;46:1586-88.